• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[中心性浆液性脉络膜视网膜病变]

[Central serous chorioretinopathy].

作者信息

Pauleikhoff Laurenz, Agostini Hansjürgen, Lange Clemens

机构信息

Klinik für Augenheilkunde, Universitätsklinikum Freiburg, Killianstr. 5, 79106, Freiburg, Deutschland.

出版信息

Ophthalmologe. 2021 Sep;118(9):967-980. doi: 10.1007/s00347-021-01376-7. Epub 2021 Apr 16.

DOI:10.1007/s00347-021-01376-7
PMID:33861376
Abstract

Central serous chorioretinopathy (CSC) is the fourth most common disease of the macula after age-related macular degeneration, diabetic retinopathy and retinal vein occlusion and a cause of irreversible visual loss. This article gives an overview of the epidemiology, risk factors, pathophysiology, clinical presentation, multimodal imaging and discusses current therapeutic options for CSC.

摘要

中心性浆液性脉络膜视网膜病变（CSC）是继年龄相关性黄斑变性、糖尿病视网膜病变和视网膜静脉阻塞之后第四常见的黄斑疾病，也是不可逆视力丧失的一个原因。本文概述了CSC的流行病学、危险因素、病理生理学、临床表现、多模态成像，并讨论了CSC目前的治疗选择。

相似文献

1
[Central serous chorioretinopathy].[中心性浆液性脉络膜视网膜病变]
Ophthalmologe. 2021 Sep;118(9):967-980. doi: 10.1007/s00347-021-01376-7. Epub 2021 Apr 16.
2
Multimodal Imaging in Fibrinous Central Serous Chorioretinopathy Compared with Exudative Maculopathy.与渗出性黄斑病变相比，纤维蛋白性中心性浆液性脉络膜视网膜病变的多模态成像
Ophthalmologica. 2020;243(5):360-369. doi: 10.1159/000504052. Epub 2020 Jan 31.
3
A rare case of diabetic macular edema with a central serous chorioretinopathy presenting as pseudohypopyon over macula.一例罕见的糖尿病性黄斑水肿合并中心性浆液性脉络膜视网膜病变，表现为黄斑区假性前房积脓。
Indian J Ophthalmol. 2020 Jan;68(1):194-196. doi: 10.4103/ijo.IJO_483_19.
4
Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy.光学相干断层扫描评估中心性浆液性脉络膜视网膜病变的脉络膜视网膜厚度及造影改变。
Ophthalmology. 2012 Aug;119(8):1666-78. doi: 10.1016/j.ophtha.2012.02.021. Epub 2012 Apr 21.
5
[Pathophysiology of macular diseases--morphology and function].黄斑疾病的病理生理学——形态与功能
Nippon Ganka Gakkai Zasshi. 2011 Mar;115(3):238-74; discussion 275.
6
Multimodal imaging findings in a case of severe Central Serous Chorioretinopathy in an uncomplicated pregnancy.一例单纯妊娠合并严重中心性浆液性脉络膜视网膜病变的多模态影像学表现
BMC Ophthalmol. 2015 Dec 22;15:183. doi: 10.1186/s12886-015-0169-x.
7
Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration.中心性浆液性脉络膜视网膜病变中伪装为新生血管性年龄相关性黄斑变性的 1 型（视网膜色素上皮下）新生血管。
Retina. 2012 Oct;32(9):1829-37. doi: 10.1097/IAE.0b013e3182680a66.
8
CONCURRENT IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 AND CENTRAL SEROUS CHORIORETINOPATHY.2型特发性黄斑毛细血管扩张症与中心性浆液性脉络膜视网膜病变并存
Retina. 2018 Jan;38 Suppl 1(Suppl 1):S67-S78. doi: 10.1097/IAE.0000000000001836.
9
Serous business: Delineating the broad spectrum of diseases with subretinal fluid in the macula.严肃的议题：黄斑部视网膜下液所涉及的广泛疾病谱。
Prog Retin Eye Res. 2021 Sep;84:100955. doi: 10.1016/j.preteyeres.2021.100955. Epub 2021 Mar 11.
10
Dark and white lesions observed in central serous chorioretinopathy on optical coherence tomography angiography.光学相干断层扫描血管造影术观察到的中心性浆液性脉络膜视网膜病变中的暗区和亮区病变
Eur J Ophthalmol. 2018 Jul;28(4):446-453. doi: 10.1177/1120672118758401. Epub 2018 Mar 19.

引用本文的文献

1
[Morphological and functional changes of secondary macular neovascularization in central serous chorioretinopathy under anti-VEGF treatment].[抗VEGF治疗下中心性浆液性脉络膜视网膜病变继发性黄斑新生血管的形态学和功能变化]
Ophthalmologie. 2025 Apr 8. doi: 10.1007/s00347-025-02221-x.
2
[Bilateral, central serous chorioretinopathy under BRAF(B-rapidly accelerated fibrosarcoma)-/MEK (mitogen-activated protein kinase kinase)-inhibitor therapy in metastatic cutaneous melanoma.].[BRAF（B-快速进展性纤维肉瘤）/MEK（丝裂原活化蛋白激酶激酶）抑制剂治疗转移性皮肤黑色素瘤期间的双侧中心性浆液性脉络膜视网膜病变。]
Ophthalmologie. 2025 Jan;122(1):52-57. doi: 10.1007/s00347-024-02140-3. Epub 2024 Dec 6.
3

本文引用的文献

1
Risk Factors and Outcome of Infection after Hematopoietic Stem Cell Transplantation.造血干细胞移植后感染的危险因素及结局
J Clin Med. 2020 Nov 16;9(11):3673. doi: 10.3390/jcm9113673.
2
Eplerenone for treatment of chronic central serous chorioretinopathy.依普利酮治疗慢性中心性浆液性脉络膜视网膜病变。
Eur J Ophthalmol. 2021 Jul;31(4):1885-1891. doi: 10.1177/1120672120952648. Epub 2020 Aug 27.
3
Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial.
The role of inflammation in central serous chorioretinopathy: From mechanisms to therapeutic prospects.
炎症在中心性浆液性脉络膜视网膜病变中的作用：从机制到治疗前景
Front Pharmacol. 2024 May 21;15:1200492. doi: 10.3389/fphar.2024.1200492. eCollection 2024.
4
Clinical Landscape of Central Serous Chorioretinopathy in Germany: Retina.net CSC Registry Report Number 1.德国中心性浆液性脉络膜视网膜病变的临床概况：Retina.net CSC 登记报告第 1 号。
Ophthalmologica. 2024;247(2):95-106. doi: 10.1159/000535930. Epub 2024 Feb 16.
5
Efficacy and safety of subthreshold micropulse laser in the treatment of acute central serous chorioretinopathy.阈下微脉冲激光治疗急性中心性浆液性脉络膜视网膜病变的疗效与安全性
Int J Ophthalmol. 2023 Jun 18;16(6):921-927. doi: 10.18240/ijo.2023.06.14. eCollection 2023.
6
SINGLE-SESSION BILATERAL REDUCED-SETTINGS PHOTODYNAMIC THERAPY FOR BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.单次双侧低强度设置的光动力疗法治疗双侧慢性中心性浆液性脉络膜视网膜病变。
Retina. 2023 Aug 1;43(8):1356-1363. doi: 10.1097/IAE.0000000000003807. Epub 2023 Jun 9.
7
Statement of the Professional Association of Ophthalmologists in Germany (BVA), the German Society of Ophthalmology (DOG) and the German Retina Society (RG) on central serous chorioretinopathy : Status 18 October 2021.德国眼科医生专业协会（BVA）、德国眼科学会（DOG）和德国视网膜协会（RG）关于中心性浆液性脉络膜视网膜病变的声明：2021年10月18日的情况
Ophthalmologie. 2022 Jul;119(Suppl 2):108-122. doi: 10.1007/s00347-022-01614-6. Epub 2022 Apr 6.
原发治疗失败后行光动力疗法或微脉冲激光光凝治疗慢性中心性浆液性脉络膜视网膜病变的随机对照研究（REPLACE 试验）。
Am J Ophthalmol. 2020 Aug;216:80-89. doi: 10.1016/j.ajo.2020.04.007. Epub 2020 Apr 11.
4
Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial.依普利酮治疗活动期、未经治疗超过 4 个月的慢性中心性浆液性脉络膜视网膜病变（VICI）患者：一项随机、双盲、安慰剂对照试验。
Lancet. 2020 Jan 25;395(10220):294-303. doi: 10.1016/S0140-6736(19)32981-2.
5
Long-term results of focal laser photocoagulation and photodynamic therapy for the treatment of central serous chorioretinopathy.中心性浆液性脉络膜视网膜病变光动力疗法和光凝治疗的长期疗效。
Jpn J Ophthalmol. 2020 Jan;64(1):28-36. doi: 10.1007/s10384-019-00697-0. Epub 2019 Dec 20.
6
The Pachychoroid Disease Spectrum-and the Need for a Uniform Classification System.肥厚脉络膜疾病谱——以及对统一分类系统的需求。
Ophthalmol Retina. 2019 Dec;3(12):1013-1015. doi: 10.1016/j.oret.2019.08.002.
7
Three-dimensional choroidal vascularity index in acute central serous chorioretinopathy using swept-source optical coherence tomography.应用扫频源光学相干断层扫描测量急性中心性浆液性脉络膜视网膜病变的脉络膜血流指数
Graefes Arch Clin Exp Ophthalmol. 2020 Feb;258(2):241-247. doi: 10.1007/s00417-019-04524-7. Epub 2019 Nov 14.
8
Central serous chorioretinopathy: Towards an evidence-based treatment guideline.中心性浆液性脉络膜视网膜病变：迈向基于证据的治疗指南。
Prog Retin Eye Res. 2019 Nov;73:100770. doi: 10.1016/j.preteyeres.2019.07.003. Epub 2019 Jul 15.
9
COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY.口服螺内酯与光动力疗法治疗未缓解的中心性浆液性脉络膜视网膜病变的视觉/解剖学结局和复发率比较。
Retina. 2020 Jun;40(6):1191-1199. doi: 10.1097/IAE.0000000000002507.
10
Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.抗醛固酮受体拮抗剂治疗未缓解中心性浆液性脉络膜视网膜病变的反应预测因素。
Am J Ophthalmol. 2019 Feb;198:80-87. doi: 10.1016/j.ajo.2018.09.034. Epub 2018 Oct 9.